Simulations Plus Acquired by Altaris for $18.50 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Source: Fool
- Acquisition Agreement: Simulations Plus has entered into a definitive agreement with investment firm Altaris to be acquired at $18.50 per share, representing a 26% premium over the 60-day volume-weighted average price as of June 15, 2026, indicating strong market confidence in the deal.
- Stock Performance: As of 11:45 a.m. today, Simulations Plus shares rose by 11.65% to $18.21, reflecting a slight discount to the acquisition price, which suggests market expectations for a smooth transaction process without competitive bidding.
- Board Approval: The all-cash transaction has been unanimously approved by Simulations Plus' board of directors, subject to customary shareholder and regulatory approvals, ensuring the deal's compliance with necessary legal frameworks.
- Integration Prospects: Altaris plans to combine Simulations Plus with its existing modeling and drug discovery software company, Chemical Computing Group, which is expected to enhance drug development efficiency and reduce R&D costs, thereby driving future growth potential for the combined entity.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLP
Wall Street analysts forecast SLP stock price to rise
5 Analyst Rating
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 18.250
Low
19.00
Averages
19.00
High
19.00
Current: 18.250
Low
19.00
Averages
19.00
High
19.00
About SLP
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Investigation Background: Halper Sadeh LLC is investigating Simulations Plus, Inc. (NASDAQ: SLP) for its sale to Altaris, LLC at $18.50 per share, potentially violating fiduciary duties and impacting shareholder rights.
- Transaction Details: Open Lending Corporation (NASDAQ: LPRO) is being sold to ANV Group Holdings Ltd. for $3.15 per share, which may not provide superior competing offers, thereby harming shareholder interests.
- Shareholder Rights Protection: Huntsman Corporation (NYSE: HUN) is selling to Olin Corporation at a rate of 0.5476 shares of Olin for each share of Huntsman, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures to protect shareholder rights.
- Legal Service Commitment: Halper Sadeh LLC offers legal services on a contingency fee basis, aiming to protect investors globally and ensure they receive compensation for securities fraud and corporate misconduct.
See More
DJS Law Group Investigates Claims for Simulations Plus Investors
- Investigation Launched: DJS Law Group announces an investigation into Simulations Plus, focusing on potential violations of securities laws that may have caused investor losses, highlighting serious concerns regarding the company's transparency.
- Investor Rights Protection: The investigation aims to determine whether Simulations Plus issued misleading statements or failed to disclose information critical to investors, reflecting potential risks in corporate governance and compliance.
- Expert Legal Support: DJS Law Group specializes in securities class actions and corporate governance litigation, committed to enhancing investor returns through balanced counseling and aggressive advocacy, demonstrating its expertise in complex legal matters.
- Strong Client Base: The firm represents some of the largest hedge funds and alternative asset managers globally, indicating its influence in the industry and the importance it places on high-value litigation.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating companies like Fathom Holdings Inc., AstroNova, Inc., and Simulations Plus, Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which could adversely affect shareholder financial interests.
- Fathom Holdings Transaction: Fathom Holdings Inc. is selling at a rate of 0.2236 shares of Bed Bath & Beyond common stock per share, potentially limiting superior competing offers, prompting shareholders to be vigilant about their rights.
- AstroNova Acquisition: AstroNova, Inc. is being sold for $29.00 per share in cash, and Halper Sadeh LLC may seek increased compensation and additional disclosures to ensure shareholders' legal rights are protected.
- Roku Transaction Details: Roku, Inc. is set to sell for $96.00 in cash and 0.9693 shares of Fox Class A common stock per share, with Halper Sadeh LLC encouraging shareholders to understand their rights and options to secure better terms in the transaction.
See More
Simulations Plus Under Investigation for Securities Violations
- Investigation Launched: Johnson Fistel, PLLP is investigating potential securities law violations by Simulations Plus, Inc., focusing on misleading statements regarding the company's financial outlook and internal controls, which could significantly impact investors.
- Revenue Guidance Cut: On June 11, 2025, Simulations Plus revised its full-year fiscal 2025 revenue guidance down from $90 million to $93 million to a range of $76 million to $80 million, primarily due to market uncertainties affecting pharmaceutical clients, leading to a direct stock price decline.
- Stock Price Volatility: Following the revenue guidance cut, Simulations Plus's stock plummeted over 24%, from $26.44 to $20.05 per share; after reporting a $67.3 million net loss on July 14, 2025, the stock fell nearly 26% again, reaching $12.97 per share.
- Audit Firm Dismissal: On July 15, 2025, Simulations Plus disclosed the dismissal of Grant Thornton LLP as its independent auditor due to unresolved issues regarding financial reporting, raising further concerns about the company's financial transparency and governance practices.
See More
Altaris to Acquire Simulations Plus in $375M All-Cash Deal
- Acquisition Agreement: Simulations Plus has entered into a definitive agreement with Altaris for an all-cash transaction valued at approximately $375 million, with shareholders set to receive $18.50 per share, representing a 26% premium over the 60-day volume-weighted average price as of June 15, 2026, providing immediate and certain value to stockholders.
- Board Approval: The acquisition has been unanimously approved by Simulations Plus's board of directors, and the deal is subject to customary shareholder and regulatory approvals, with completion expected in the fourth quarter of 2026, marking a significant strategic shift for the company.
- Integration and Innovation: Altaris plans to combine Simulations Plus with Chemical Computing Group (CCG) from its portfolio, aiming to build a more comprehensive biosimulation platform for drug discovery and development, enhancing customer support throughout the entire research and development lifecycle.
- Market Impact and Outlook: Following the acquisition, Simulations Plus is expected to become a privately held subsidiary of Altaris, which is anticipated to accelerate innovation in the life sciences sector, particularly in AI-driven platforms and cloud-based infrastructure, aligning with the industry's shift towards integrated and predictable subscription models.
See More
CervoMed and Others See Significant Stock Gains
- CervoMed Clinical Progress: CervoMed's lead drug candidate Neflamapimod has completed enrollment in its Phase 2a trial in the US, with 24-week biomarker data expected in Q4 2023, which will significantly bolster its market potential in treating dementia.
- Conexeu Leadership Expansion: Conexeu Sciences expanded its board from six to nine members and appointed a Chief Commercial Officer to accelerate the development of its 3D-printed bioregenerative breast matrix, aiming to enhance market execution and growth potential.
- NeOnc International Regulatory Approval: NeOnc Technologies received regulatory clearance from the Department of Health - Abu Dhabi to initiate a Phase 2 trial of NEO212 for aggressive brain tumors, marking a significant step in its international development and enhancing its competitive position.
- Simulations Plus Acquisition Agreement: Simulations Plus has agreed to be acquired by Altaris for $375 million, with shareholders set to receive $18.50 per share, representing a premium, and the transaction is expected to close in Q4 2023, providing new capital and resources for future growth.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Investigation Background: Halper Sadeh LLC is investigating Simulations Plus, Inc. (NASDAQ: SLP) for its sale to Altaris, LLC at $18.50 per share, potentially violating fiduciary duties and impacting shareholder rights.
- Transaction Details: Open Lending Corporation (NASDAQ: LPRO) is being sold to ANV Group Holdings Ltd. for $3.15 per share, which may not provide superior competing offers, thereby harming shareholder interests.
- Shareholder Rights Protection: Huntsman Corporation (NYSE: HUN) is selling to Olin Corporation at a rate of 0.5476 shares of Olin for each share of Huntsman, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures to protect shareholder rights.
- Legal Service Commitment: Halper Sadeh LLC offers legal services on a contingency fee basis, aiming to protect investors globally and ensure they receive compensation for securities fraud and corporate misconduct.
See More
DJS Law Group Investigates Claims for Simulations Plus Investors
- Investigation Launched: DJS Law Group announces an investigation into Simulations Plus, focusing on potential violations of securities laws that may have caused investor losses, highlighting serious concerns regarding the company's transparency.
- Investor Rights Protection: The investigation aims to determine whether Simulations Plus issued misleading statements or failed to disclose information critical to investors, reflecting potential risks in corporate governance and compliance.
- Expert Legal Support: DJS Law Group specializes in securities class actions and corporate governance litigation, committed to enhancing investor returns through balanced counseling and aggressive advocacy, demonstrating its expertise in complex legal matters.
- Strong Client Base: The firm represents some of the largest hedge funds and alternative asset managers globally, indicating its influence in the industry and the importance it places on high-value litigation.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating companies like Fathom Holdings Inc., AstroNova, Inc., and Simulations Plus, Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which could adversely affect shareholder financial interests.
- Fathom Holdings Transaction: Fathom Holdings Inc. is selling at a rate of 0.2236 shares of Bed Bath & Beyond common stock per share, potentially limiting superior competing offers, prompting shareholders to be vigilant about their rights.
- AstroNova Acquisition: AstroNova, Inc. is being sold for $29.00 per share in cash, and Halper Sadeh LLC may seek increased compensation and additional disclosures to ensure shareholders' legal rights are protected.
- Roku Transaction Details: Roku, Inc. is set to sell for $96.00 in cash and 0.9693 shares of Fox Class A common stock per share, with Halper Sadeh LLC encouraging shareholders to understand their rights and options to secure better terms in the transaction.
See More
Simulations Plus Under Investigation for Securities Violations
- Investigation Launched: Johnson Fistel, PLLP is investigating potential securities law violations by Simulations Plus, Inc., focusing on misleading statements regarding the company's financial outlook and internal controls, which could significantly impact investors.
- Revenue Guidance Cut: On June 11, 2025, Simulations Plus revised its full-year fiscal 2025 revenue guidance down from $90 million to $93 million to a range of $76 million to $80 million, primarily due to market uncertainties affecting pharmaceutical clients, leading to a direct stock price decline.
- Stock Price Volatility: Following the revenue guidance cut, Simulations Plus's stock plummeted over 24%, from $26.44 to $20.05 per share; after reporting a $67.3 million net loss on July 14, 2025, the stock fell nearly 26% again, reaching $12.97 per share.
- Audit Firm Dismissal: On July 15, 2025, Simulations Plus disclosed the dismissal of Grant Thornton LLP as its independent auditor due to unresolved issues regarding financial reporting, raising further concerns about the company's financial transparency and governance practices.
See More
Altaris to Acquire Simulations Plus in $375M All-Cash Deal
- Acquisition Agreement: Simulations Plus has entered into a definitive agreement with Altaris for an all-cash transaction valued at approximately $375 million, with shareholders set to receive $18.50 per share, representing a 26% premium over the 60-day volume-weighted average price as of June 15, 2026, providing immediate and certain value to stockholders.
- Board Approval: The acquisition has been unanimously approved by Simulations Plus's board of directors, and the deal is subject to customary shareholder and regulatory approvals, with completion expected in the fourth quarter of 2026, marking a significant strategic shift for the company.
- Integration and Innovation: Altaris plans to combine Simulations Plus with Chemical Computing Group (CCG) from its portfolio, aiming to build a more comprehensive biosimulation platform for drug discovery and development, enhancing customer support throughout the entire research and development lifecycle.
- Market Impact and Outlook: Following the acquisition, Simulations Plus is expected to become a privately held subsidiary of Altaris, which is anticipated to accelerate innovation in the life sciences sector, particularly in AI-driven platforms and cloud-based infrastructure, aligning with the industry's shift towards integrated and predictable subscription models.
See More
CervoMed and Others See Significant Stock Gains
- CervoMed Clinical Progress: CervoMed's lead drug candidate Neflamapimod has completed enrollment in its Phase 2a trial in the US, with 24-week biomarker data expected in Q4 2023, which will significantly bolster its market potential in treating dementia.
- Conexeu Leadership Expansion: Conexeu Sciences expanded its board from six to nine members and appointed a Chief Commercial Officer to accelerate the development of its 3D-printed bioregenerative breast matrix, aiming to enhance market execution and growth potential.
- NeOnc International Regulatory Approval: NeOnc Technologies received regulatory clearance from the Department of Health - Abu Dhabi to initiate a Phase 2 trial of NEO212 for aggressive brain tumors, marking a significant step in its international development and enhancing its competitive position.
- Simulations Plus Acquisition Agreement: Simulations Plus has agreed to be acquired by Altaris for $375 million, with shareholders set to receive $18.50 per share, representing a premium, and the transaction is expected to close in Q4 2023, providing new capital and resources for future growth.
See More
